

GlyTech and Bachem Named Finalist for CPhI Pharma Award for Best Innovation in Process Development.

Kyoto (Japan), 23 October 2013 – On 22th, October 2013 in Frankfurt, Germany, GlyTech and Bachem were selected as one of three finalists for the 2013 CPhI Pharma Award for Best Innovation in Process Development. Although not ultimately winning the award, being selected as a finalist represents significant validation of the value of the technology and collaboration. The award ceremony took place on the same day as part of the annual CPhI Worldwide exhibition, which attracted approximately 30,000 attendees from the pharmaceutical industry.

GlyTech and Bachem had been selected as a finalist following their development of the first industrially-viable production of human Interferon beta-1a, 166 amino acid glycoprotein, via a fully-synthetic process. In contrast to the traditional recombinant approach which yields a mixture of at least ten glycoforms, chemical synthesis renders a single, homogeneous glycoprotein with a high purity. The chemically-synthesized protein was fully functional, and in a xenograft mouse model, in vivo anti-tumor activity was demonstrated to be as good as or better than that of commercial Interferon β -1a.

GlyTech and Bachem are seeking a partner to take this product through clinical development.

About GlyTech

GlyTech is an independent, technology-based, private company founded in 2012 in Kyoto, Japan. GlyTech is the only company to manufacture human type glycan in KG scale and developing unique glycopeptides and glycoproteins as innovative biochemicals, which the current expression systems are enable to produce, with glycan conjugation technologies.

Contact:

For further questions, please visit our website or contact the person below.

GlyTech, Inc.

Katsura Torii, CBDO

Tel: +81 75 315 9218

Fax: +81 75 315 9225

glytech-info@glytech.jp

www.glytech.jp